Australia markets closed

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.1500-0.0900 (-7.26%)
At close: 04:00PM EST
1.1500 0.00 (0.00%)
After hours: 08:00PM EST

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919 806 1074
https://www.chimerix.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees89

Key executives

NameTitlePayExercisedYear born
Mr. Michael T. Andriole M.B.A.CEO, President & Director592.95kN/A1973
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer605.29kN/A1964
Ms. Michelle LaSpalutoChief Financial OfficerN/AN/A1974
Mr. Thomas J. RigaChief Operating & Commercial OfficerN/AN/A1975
Mr. David Jakeman CPAVP of Accounting & FinanceN/AN/A1977
Dr. Joshua E. Allen Ph.D.Chief Technology OfficerN/AN/AN/A
Dr. Michael A. Alrutz J.D., Ph.D.Senior VP, General Counsel & Corporate Secretary619.5kN/A1970
Dr. Roy W. Ware MBA, Ph.D.Chief Manufacturing Technology OfficerN/AN/AN/A
Dr. Pablo Lee M.D.Head of Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Corporate governance

Chimerix, Inc.’s ISS governance QualityScore as of 28 February 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.